{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:36:20Z","timestamp":1792805780914,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.kisu.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:13:49Z","timestamp":1784538829000},"page":"24-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence"],"prefix":"10.1016","volume":"15","author":[{"given":"Sayna","family":"Norouzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lafayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2026.03.001_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.03.001_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-024-02036-1","article-title":"Drugs in development to treat IgA nephropathy","volume":"84","author":"Del Vecchio","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.kisu.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.kisu.2026.01.002","article-title":"Management of IgA nephropathy and the expanding role of immunomodulation","volume":"15","author":"Canetta","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.03.001_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.03.001_bib29","series-title":"Tarpeyo\u00ae (targeted release formulation budesonide) US prescribing information","year":"2024"},{"key":"10.1016\/j.kisu.2026.03.001_bib30","series-title":"Filspari\u00ae (sparsentan) US prescribing information","year":"2025"},{"key":"10.1016\/j.kisu.2026.03.001_bib31","series-title":"Fabhalta\u00ae (iptacopan) US prescribing information","year":"2025"},{"key":"10.1016\/j.kisu.2026.03.001_bib32","series-title":"Vanrafia\u00ae (atrasentan) US prescribing information","year":"2025"},{"key":"10.1016\/j.kisu.2026.03.001_bib33","series-title":"Kinpeygo\u00ae (targeted release formulation budesonide) summary of product characteristics","year":"2025"},{"key":"10.1016\/j.kisu.2026.03.001_bib37","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.03.001_bib39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.03.001_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy \u2013 interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.03.001_bib43","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.03.001_bib44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.03.001_bib45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.03.001_bib46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.03.001_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2026.03.001_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.03.001_bib51","article-title":"eGFR slope modelling predicts long-term clinical benefit with nefecon in a real-world IgAN population","volume":"18","author":"Barratt","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2026.03.001_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kisu.2026.01.004","article-title":"The expanding role of biomarkers in the management of IgA nephropathy","volume":"15","author":"Jain","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.03.001_bib53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","article-title":"Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy","volume":"20","author":"Trachtman","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.kisu.2026.03.001_bib54","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.kisu.2026.03.001_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.03.001_bib56","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes","volume":"35","author":"Ku","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.03.001_bib57","doi-asserted-by":"crossref","first-page":"F862","DOI":"10.1152\/ajprenal.00253.2023","article-title":"Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy","volume":"326","author":"Reily","year":"2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kisu.2026.03.001_bib60","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in IgA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.03.001_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ekir.2024.10.004","article-title":"Study design and baseline characteristics of ALIGN, a randomized controlled study of atrasentan in patients with IgA nephropathy","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.03.001_bib62","doi-asserted-by":"crossref","first-page":"1346769","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front Nephrol"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:57:14Z","timestamp":1785995834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171626000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2157171626000055"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2026.03.001","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2025.12.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}